Explore

Trendline Trendline
AI-Designed Protein Switches Revolutionize Low-Cost Biosensors for Medicine and Environment

AI-Designed Protein Switches Revolutionize Low-Cost Biosensors for Medicine and Environment

AI-Designed Protein Switches Revolutionize Low-Cost Biosensors for Medicine and Environment
Rapid Read Rapid Read
Rockefeller University Researchers Develop Platform to Target Melanoma Drug Resistance

Rockefeller University Researchers Develop Platform to Target Melanoma Drug Resistance

Researchers at The Rockefeller University have developed a platform called PerturbFate, which systematically maps how genetic variations associated with diseases reshape cells. The study, published in Nature, focuses on melanoma drug resistance, identifying regulatory nodes common to diverse genetic variations. This approach offers a path toward combination therapies that can target diseases across various genetic causes. The platform allows researchers to observe genetic changes in real-time, tracking DNA accessibility and RNA production. By analyzing over 300,000 cells, the study found that diverse genetic perturbations pushed melanoma cells into a drug-resistant state, which could be mitigated by targeting common control points.
Trendline Trendline
Vir Biotechnology Begins Phase 1 Trial for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Trial for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Trial for Prostate Cancer Treatment
Trendline Trendline
Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline
Rapid Read Rapid Read
FDA Grants RMAT Designation to Grace Science's GS-100 Gene Therapy for NGLY1 Deficiency

FDA Grants RMAT Designation to Grace Science's GS-100 Gene Therapy for NGLY1 Deficiency

The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GS-100, a gene therapy developed by Grace Science, LLC, for treating NGLY1 Deficiency. This ultra-rare genetic disease affects children and currently has no approved therapies. GS-100 is an investigational adeno-associated viral vector therapy designed to replace the deficient NGLY1 protein. The RMAT designation is based on promising early clinical evidence showing improvements in motor function and cognitive skills in patients treated with GS-100. This designation aims to expedite the development and review process, potentially leading to accelerated approval.
Trendline Trendline
Alida Biosciences Unveils EpiPlex Tri-Mod Service for mRNA Modification Profiling

Alida Biosciences Unveils EpiPlex Tri-Mod Service for mRNA Modification Profiling

Alida Biosciences Unveils EpiPlex Tri-Mod Service for mRNA Modification Profiling
Trendline Trendline
Invivoscribe Launches PrepQuant System to Enhance Molecular Testing Consistency

Invivoscribe Launches PrepQuant System to Enhance Molecular Testing Consistency

Invivoscribe Launches PrepQuant System to Enhance Molecular Testing Consistency
Rapid Read Rapid Read
Stanford Researchers Develop Noninvasive Light Delivery Method Using Ultrasound

Stanford Researchers Develop Noninvasive Light Delivery Method Using Ultrasound

Researchers at Stanford University have developed a novel method to deliver light to specific locations within the body noninvasively. This technique, published in Nature Materials, utilizes nanomaterials that convert ultrasound waves into precise points of light. The method allows for light-based treatments without the need for invasive procedures like tissue removal or optical fiber insertion. The research team, led by Guosong Hong, demonstrated the potential of this technology by using it to stimulate neurons in mice, causing behavioral changes. The technique could have applications in photodynamic therapy for cancer and other light-based treatments, pending further development of safer, biodegradable materials.
Rapid Read Rapid Read
Stanford Researchers Develop Ultrasound-Activated Nanoparticles for Deep-Tissue Light Therapy

Stanford Researchers Develop Ultrasound-Activated Nanoparticles for Deep-Tissue Light Therapy

Researchers at Stanford University have developed a groundbreaking nanotechnology that uses non-invasive ultrasound to create light inside the body. This innovation allows for the delivery of light to any part of the body without the need for invasive procedures. The technology involves mechanoluminescent nanoparticles that emit blue light when stimulated by ultrasound waves. These nanoparticles are coated with a biocompatible material and can be injected into the bloodstream, where they travel throughout the body. The research demonstrated the ability to generate light in multiple locations simultaneously, offering precise control over light emission. This method has potential applications in various medical fields, including surgery and targeted therapies, by overcoming the limitations of light penetration in tissues.
Rapid Read Rapid Read
Oregon State University Researchers Develop Promising Lung Cancer Treatment Using Lipid Nanoparticles

Oregon State University Researchers Develop Promising Lung Cancer Treatment Using Lipid Nanoparticles

Researchers at Oregon State University have developed a novel approach to address two major challenges associated with lung cancer: tumor growth and severe muscle loss. Their study, published in the Journal of Controlled Release, explores the use of lipid nanoparticles to deliver genetic material directly to cancer cells in the lungs. These nanoparticles are engineered to carry follistatin messenger RNA, which instructs cells to produce follistatin, a protein that slows tumor progression and supports muscle growth. The lipid nanoparticles are administered through the bloodstream and are directed to lung cancer tumors by binding with vitronectin, a protein found in blood serum. This method has shown a 2.5-fold greater reduction in tumor burden compared to conventional lipid nanoparticles, which tend to accumulate in the liver.
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal
Trendline Trendline
BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial